Finerenone is a novel, nonsteroidal mineralocorticoid receptor antagonist (MRA) that has recently received regulatory approval with the indication of cardiorenal protection in patients with CKD associated with type 2 diabetes (T2D). This evidence concerns the gene NR3C2 and type 2 diabetes mellitus.